Daily image guided radiotherapy (IGRT)
Since opening, GenesisCare has acquired an immense data base of information about treating patients using daily online image guided radiotherapy (IGRT). In order to utilise the vast amount of information that has been collected, in March 2013 GenesisCare established their own Research and Development team.
Not many cancer centres in the UK are able to offer daily image guided treatment, and although it seems sensible to use daily IGRT to ensure the high dose of radiation is delivered to the correct location for every fraction, there is limited published literature on it in the UK. For this reason, the first project the Research and Development team have undertaken is a revision of the benefits of daily IGRT over non-daily methods for prostate treatments.
XVI data for a sample of patients across GenesisCare’s first four centres has been collected and the Research and Development team are using these XVIs in the treatment planning system to estimate the actual radiation dose that delivered on each fraction to the prostate, rectum & bladder. They are then comparing what would have been delivered with a non-daily IGRT protocol.
The GenesisCare Research and Development team have already received acclaim for their work, when in April 2014, their initial findings were presented at ESTRO33, the largest annual radiotherapy conference in Europe, and were awarded first prize for a poster entitled Reduced PTV margins for prostate IMRT with daily online IGRT: a retrospective analysis, which you can view here.
A side study of this major project is the revision of GenesisCare’s planning target volume margin which is currently 7mm to see if the use of daily IGRT will allow for a reduction in this margin. Reducing the margin has the potential to reduce bladder and rectal doses; however it should only be reduced if the prescribed radiation dose can still be safely delivered to the entire prostate.
Deep inspiration breath-hold (DIBH)
This type of treatment is designed to be more accurate than other treatments available and to minimise risk to other vital organs in the body. Specifically, it significantly reduces radiation to the heart and surrounding critical organ tissue in the chest.
GenesisCare has conducted a significant piece of research into spirometry-monitored deep inspiration breath-hold radiotherapy (DIBH).
The research was peer reviewed at the 3rd ESTRO Forum in Barcelona, in April 2015.
The research findings can be found in this whitepaper.
GenesisCare is fully committed to implementing the best practices resulting from this growing body of research as well as contributing ourselves by publishing the results of our own work and experience.
View a selection of our own publications describing the latest techniques and technology available now to clinicians and patients at all our centres.
In recent years there have been huge leaps forward in the technology and methods available for delivering external beam radiotherapy. There are many centres of excellence across Europe and the United States conducting cutting edge research and publishing the results of exciting clinical trials. View a selection of the latest papers.